Tuesday Educational Symposia during the ISPOR 12th European Congress

Tuesday 27 October 2009 7:00-8:00

Compliance and Persistence: Capturing the Economic Benefits

Continental breakfast provided before the symposium

Poor adherence to medication not only represents the primary reason for suboptimal clinical benefit from treatment, but is also associated with a significant economic burden.
Attempts to quantify and describe the extent of the problem in a ‘real world’ population are hindered by the variety of underlying causes and the difficulties posed in monitoring and surveillance.

This symposium addresses the clinical and financial impact of poor adherence, using the example of osteoporosis, a common chronic disease.

The presentations will examine the causes of poor adherence in clinical practice, present possible solutions to this issue, discuss the role of patient-reported data alongside other options for measuring adherence, and review current approaches for translating improved adherence into economic evaluations.

Symposium Presentation

View Presentation

WELCOME AND INTRODUCTION
Speaker: Rob Horne MSc, PhD, MRPharmS, Head of the Department of Practice and Policy, Director of the Centre of Behavioural Medicine, and Professor of Behavioural Medicine, The School of Pharmacy, University of London, London, UK

UNDERSTANDING POOR ADHERENCE: CAUSES AND SOLUTIONS
Speaker: Rob Horne MSc, PhD, MRPharmS, Head of the Department of Practice and Policy, Director of the Centre of Behavioural Medicine, and Professor of Behavioural Medicine, The School of Pharmacy, University of London, London, UK

MEASURING ADHERENCE IN THE REAL WORLD
Speaker: Tjeerd-Pieter van Staa MD, PhD, MSc, MA, Head of Research, General Practice Research Database, London, UK, Associate Professor, Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands and Visiting Lecturer, School of Medicine, University of Southampton, Southampton, UK

THE ECONOMIC VALUE OF IMPROVED ADHERENCE
Speaker: Oskar Ström MSc, Associate Director, i3 Innovus, Stockholm, Sweden.

DISCUSSION AND CONCLUSION

Sponsored by Amgen

Tuesday Educational Symposia during the ISPOR 12th European Congress

Tuesday 27 October 2009 11:45-12:45

Regulatory Review and Health Technology Assessment (HTA) - Opportunities and Limitations of an Integrative Approach

Regulators and payers play different roles in determining patient access to innovative therapies: regulators focus on risk/benefit assessments to authorise utilisation whereas payers use HTAs to determine pricing, reimbursement, or funding conditions in the context of local budget constraints and relevant alternative treatment options.

Satisfying both regulatory and HTA requirements creates a large and increasing burden on patients in terms of potentially delayed access and on innovative pharmaceutical manufacturers in terms of time, effort and money.

Because of their different roles, regulatory reviews and HTAs have to apply different evidentiary and analytical standards. However increasingly, even where regulatory and HTA objectives overlap, standards differ. In these areas, all stakeholders could benefit from a more coordinated approach.

The symposium provides the opportunity to discuss ongoing efforts and new initiatives in this field and the possibilities to realize the expected benefits.

Symposium Presentation

View Presentation

INTRODUCTION: EFPIA'S HTA PRINCIPLES

Speaker: Ansgar Hebborn PhD, Head, Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

MARKETING AUTHORISATION AND HTA: THE EMEA POSITION

Speaker: Eric Abadie MD, MBA, Chairman of the Committee for Medicinal Products for Human Use, EMEA and Scientific Advisor to the General Director, AFSSAPS, Saint Denis, France

REIMBURSEMENT, HTA AND REGULATORY AGENCIES: MODALITIES OF INCREASED COOPERATION

Speaker: Ad Schuurman MBA, Head of Reimbursement, Dutch Health Care Insurance Board and President, Medicine Evaluation Committee, Diemen, The Netherlands

ADDRESSING THE NEEDS OF REIMBURSEMENT AND LICENSING AUTHORITIES AT THE SAME TIME: CHALLENGES AND OPPORTUNITIES FOR INDUSTRY

Speaker: Clare McGrath, Senior Director, HTA Policy, Pfizer, Tadworth, Surrey, UK

PANEL DISCUSSION

Sponsored by European Federation of Pharmaceutical Industries and Associations (EFPIA)